- Reaction score
- 28
Prefatory quote: "100% of the subjects treated to date with RT1640 have responded with robust hair growth, and in several instances, complete restoration of the hair. Unlike other treatments on the market, RT1640 is effective in both men and women, irrespective of age or the duration of hair loss."
The aforementioned company "RiverTown Therapeutics" has recently launched its website! (I discovered this through folliclethought's website). You should all take a look at the site. As we know, they won "Best in Show" at the Mid Atlantic Bio Angels 1st Pitch Life Science Competition a little while ago with their RT1640 compound. They talked about patients gaining a lot of hair using the treatment, and they are sticking by it on their website.
http://www.rivertowntherapeutics.com/home/
They seem to be taking a different approach to hairloss in a much more promising way. Rather than targeting a specific pathway, they talk about their compound being composed of 3 different molecules in order to target 3 different pathways at once. Several of the quotes below show that they seem to have a pretty good understanding of what they are doing. The fact that they acknowledge current treatments are partially effective at best, and some having huge side affects tells me they have a better realization of the current situation. They are specifically targeting male pattern baldness, so no worries. You can get all the following information from their website, but I am putting it here for ease of access in one place.
"By any definition, androgenic alopecia (Androgenetic Alopecia) is an unmet medical need, with over 90 million men and women affected in the US alone. The current available treatments for Androgenetic Alopecia are at best, partially effective, with some having serious potential side effects. Even with the limited treatment choices now available, the US market for hair restoration is estimated at $4B, with no dominant company. In spite of the size of the market, there is currently no single dominant company."
"RiverTown Therapeutics Inc. is committed to using our proprietary combinatorial small molecule platform to regenerate hair by reversing androgenic alopecia (male pattern baldness) and other hair loss."
They also have this quote on their site:
A 2014 paper in the journal Expert Opinion on Therapeutic Targets stated: “It is unlikely that single targeted agents will be sufficient for treating Androgenetic Alopecia, and therefore, it would be a challenge to obtain compounds with multiple activities
AND...
"The RTI scientific founder, David E. Weinstein, MD, PhD reached a similar conclusion. To overcome this hurdle, he developed RT1640, which consists of three active agents formulated for twice daily application. The three drugs synergize to promote the recruitment of new hair follicles, and/or rejuvenate existing follicles that have become dormant, a normal event in Androgenetic Alopecia. 100% of the subjects treated to date with RT1640 have responded with robust hair growth, and in several instances, complete restoration of the hair. Unlike other treatments on the market, RT1640 is effective in both men and women, irrespective of age or the duration of hair loss."
Here they talk about ingredients and trials:
"Two of the three active agents in RT1640, cyclosporine A and Minoxidil, are FDA approved and off patent. They are known to be safe for use on the skin, and there are thousands of people-year exposures to these drugs. The third active ingredient in RT1640, is a new chemical entity (NCE) called RT175. Created by one of the RiverTown co-founders, it has been tested in over 600 humans in FDA sanctioned clinical trials. RT175 has an outstanding safety profile, with no serious adverse events associated with its use."
“RT1640 is made up of three small molecule drugs that together synergize to act on three distinct pathways in hair biology. One drug promotes the growth and migration of new stem cells, one drug promotes the commitment of the follicular stem cells to become new hair and one protects the dermal papilla from the effects of DHT.”
Here is a picture from their pipeline page:
The aforementioned company "RiverTown Therapeutics" has recently launched its website! (I discovered this through folliclethought's website). You should all take a look at the site. As we know, they won "Best in Show" at the Mid Atlantic Bio Angels 1st Pitch Life Science Competition a little while ago with their RT1640 compound. They talked about patients gaining a lot of hair using the treatment, and they are sticking by it on their website.
http://www.rivertowntherapeutics.com/home/
They seem to be taking a different approach to hairloss in a much more promising way. Rather than targeting a specific pathway, they talk about their compound being composed of 3 different molecules in order to target 3 different pathways at once. Several of the quotes below show that they seem to have a pretty good understanding of what they are doing. The fact that they acknowledge current treatments are partially effective at best, and some having huge side affects tells me they have a better realization of the current situation. They are specifically targeting male pattern baldness, so no worries. You can get all the following information from their website, but I am putting it here for ease of access in one place.
"By any definition, androgenic alopecia (Androgenetic Alopecia) is an unmet medical need, with over 90 million men and women affected in the US alone. The current available treatments for Androgenetic Alopecia are at best, partially effective, with some having serious potential side effects. Even with the limited treatment choices now available, the US market for hair restoration is estimated at $4B, with no dominant company. In spite of the size of the market, there is currently no single dominant company."
"RiverTown Therapeutics Inc. is committed to using our proprietary combinatorial small molecule platform to regenerate hair by reversing androgenic alopecia (male pattern baldness) and other hair loss."
They also have this quote on their site:
A 2014 paper in the journal Expert Opinion on Therapeutic Targets stated: “It is unlikely that single targeted agents will be sufficient for treating Androgenetic Alopecia, and therefore, it would be a challenge to obtain compounds with multiple activities
AND...
"The RTI scientific founder, David E. Weinstein, MD, PhD reached a similar conclusion. To overcome this hurdle, he developed RT1640, which consists of three active agents formulated for twice daily application. The three drugs synergize to promote the recruitment of new hair follicles, and/or rejuvenate existing follicles that have become dormant, a normal event in Androgenetic Alopecia. 100% of the subjects treated to date with RT1640 have responded with robust hair growth, and in several instances, complete restoration of the hair. Unlike other treatments on the market, RT1640 is effective in both men and women, irrespective of age or the duration of hair loss."
Here they talk about ingredients and trials:
"Two of the three active agents in RT1640, cyclosporine A and Minoxidil, are FDA approved and off patent. They are known to be safe for use on the skin, and there are thousands of people-year exposures to these drugs. The third active ingredient in RT1640, is a new chemical entity (NCE) called RT175. Created by one of the RiverTown co-founders, it has been tested in over 600 humans in FDA sanctioned clinical trials. RT175 has an outstanding safety profile, with no serious adverse events associated with its use."
“RT1640 is made up of three small molecule drugs that together synergize to act on three distinct pathways in hair biology. One drug promotes the growth and migration of new stem cells, one drug promotes the commitment of the follicular stem cells to become new hair and one protects the dermal papilla from the effects of DHT.”
Here is a picture from their pipeline page:
Last edited:
